Dizal (Jiangsu) Pharmaceutical Co., Ltd. (688192.SH): Multiple Latest Research Findings in Lung Cancer Field Announced at 2025 World Conference on Lung Cancer (WCLC)

Stock News09-09

Dizal (Jiangsu) Pharmaceutical Co., Ltd. (688192.SH) announced that the company reported 11 latest studies of its self-developed novel lung cancer targeted drug Suvozertinib® (generic name: Suvozertinib tablets) and highly selective JAK1 inhibitor Golcadomide® (generic name: Golcadomide capsules) in the non-small cell lung cancer (NSCLC) field at the 2025 World Conference on Lung Cancer (WCLC) held from September 6-9, 2025. Among these, the latest research results from Suvozertinib®'s international multicenter registration clinical study "WU-KONG1B" were presented as an oral report at the conference.

The latest research results from Suvozertinib®'s first international multicenter registration clinical study "WU-KONG1B" demonstrate that Suvozertinib® shows a favorable benefit/risk ratio in second/later-line treatment of epidermal growth factor receptor (EGFR) exon 20 insertion mutation (Exon20ins) NSCLC: significant and durable anti-tumor efficacy with controllable and manageable safety profile.

In July 2025, Suvozertinib® received approval for marketing in the United States through priority review based on the "WU-KONG1B" study, making it currently the only approved oral small molecule targeted therapy globally for treating EGFR Exon20ins NSCLC.

The company also announced the latest exploration of Golcadomide® in NSCLC treatment at WCLC. The study shows that Golcadomide® combined with anti-PD-1 monoclonal antibody for treating advanced NSCLC patients previously treated with PD-1 therapy showed no dose-limiting toxicity (DLT) in the dose escalation phase. The study is currently ongoing with continued enrollment and data collection, which will provide important evidence for the clinical application of Golcadomide® in NSCLC.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment